UNSPSC 41131707: Factor v leiden dna mutation detection systems

In this classification Factor V Leiden deoxyribonucleic acid (DNA) mutation detection systems are devices that consist of different reagents and instruments which include polymerase chain reaction (PCR) primers, hybridization matrices, thermal cyclers, imagers, and software packages US FDA regulates Factor v leiden dna mutation detection systems under 21 CFR 864.7280 and under FDA product code NPQ.

UNSPSC 41131707 Factor v leiden DNA mutation detection systems, a Commodity code, shows substantial recent mismatch between its nominal scope and actual state and local procurement activity. The code's catalog name denotes genetic testing for thrombosis risk, yet recent opportunities across the source solicitations center on drug testing, specimen collection, laboratory consumables, forensic analysis supplies, occupational health screening, and controlled-substance detection—none of which align with Factor V Leiden mutation analysis. State and local governments are using this code designation to buy drug-screening panels, urinalysis services, immunoassay and confirmation testing (LC/MS/MS, GC/MS), forensic drug standards, naloxone, blood-draw kits, and laboratory supplies for toxicology and seized-drug analysis. The issuing bodies span county community supervision departments, county health care services, county forensic laboratories, municipal public health agencies, county public safety, state departments, and educational institutions. Collin County Community Supervision and Corrections Department (Texas), Gwinnett County (Georgia), Seminole County (Florida), Benton County (Oregon), and Pinellas County (Florida) appear as repeat buyers of drug-testing services and related supplies; Texas state procurement also solicited specialized laboratory consumables for forensic and drug-screening applications.

Geographic activity concentrates in Texas, Florida, Georgia, and Oregon, with additional recent solicitations from North Carolina and New Mexico. Representative recent opportunities include Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services, due July 23, 2026, with estimated contract value of $600,000 and annual testing demand of approximately 25,031 tests across five-panel and six-panel screening with LC/MS/MS or GC/MS confirmation; the Texas Comptroller of Public Accounts Statewide Procurement Division's IFB 304T-27-175A1.1 for proprietary chemical laboratory equipment and supplies (genetic analyzer components, DNA sequencing kits, and Direct ELISA kits for controlled-substance detection), due October 20, 2026; Benton County, Oregon's RFQ for urinalysis testing services for the Family Treatment Court Program, due July 6, 2026, requiring twice-weekly testing with 48–72 hour result turnaround; and Pinellas County, Florida's ITQ 26-0305-ITQ for certified reference materials (drug standards) for forensic analysis, due April 23, 2026, with $72,126.85 in federal funding through the Paul Coverdell Forensic Sciences Improvement Act Program. The code exhibits active procurement volume but represents a cataloging error—no recent opportunities address genetic mutation detection for thrombophilia or hereditary risk assessment.